219 related articles for article (PubMed ID: 23517644)
1. Inhalation delivery of protein therapeutics.
Kane C; O'Neil K; Conk M; Picha K
Inflamm Allergy Drug Targets; 2013 Apr; 12(2):81-7. PubMed ID: 23517644
[TBL] [Abstract][Full Text] [Related]
2. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
[TBL] [Abstract][Full Text] [Related]
3. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
[TBL] [Abstract][Full Text] [Related]
4. Oral inhalation for delivery of proteins and peptides to the lungs.
Fröhlich E; Salar-Behzadi S
Eur J Pharm Biopharm; 2021 Jun; 163():198-211. PubMed ID: 33852968
[TBL] [Abstract][Full Text] [Related]
5. Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems.
Woods A; Andrian T; Sharp G; Bicer EM; Vandera KA; Patel A; Mudway I; Dailey LA; Forbes B
Eur J Pharm Biopharm; 2020 Jan; 146():64-72. PubMed ID: 31756380
[TBL] [Abstract][Full Text] [Related]
6. Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System.
Phillips JE; Zhang X; Johnston JA
J Vis Exp; 2017 Apr; (122):. PubMed ID: 28448027
[TBL] [Abstract][Full Text] [Related]
7. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities.
Rinderknecht CH; Ning M; Wu C; Wilson MS; Gampe C
Expert Opin Drug Discov; 2024 Apr; 19(4):493-506. PubMed ID: 38407117
[TBL] [Abstract][Full Text] [Related]
8. Inhaled Biologics: From Preclinical to Product Approval.
Fathe K; Ferrati S; Moraga-Espinoza D; Yazdi A; Smyth HD
Curr Pharm Des; 2016; 22(17):2501-21. PubMed ID: 26861725
[TBL] [Abstract][Full Text] [Related]
9. Inhaled Drug Therapy 2016: The Year in Review.
Dhand R
Respir Care; 2017 Jul; 62(7):978-996. PubMed ID: 28559466
[TBL] [Abstract][Full Text] [Related]
10. Nanobodies® as inhaled biotherapeutics for lung diseases.
Van Heeke G; Allosery K; De Brabandere V; De Smedt T; Detalle L; de Fougerolles A
Pharmacol Ther; 2017 Jan; 169():47-56. PubMed ID: 27373507
[TBL] [Abstract][Full Text] [Related]
11. Barriers for orally inhaled therapeutic antibodies.
Sécher T; Heuzé-Vourc'h N
Expert Opin Drug Deliv; 2023; 20(8):1071-1084. PubMed ID: 37609943
[TBL] [Abstract][Full Text] [Related]
12. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.
Newman SP
Adv Drug Deliv Rev; 2018 Aug; 133():5-18. PubMed ID: 29653129
[TBL] [Abstract][Full Text] [Related]
13. Inhaled Formulation Design for the Treatment of Lung Infections.
Garcia-Contreras L; Yadav KS
Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology approaches for inhalation treatment of lung diseases.
Kuzmov A; Minko T
J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
[TBL] [Abstract][Full Text] [Related]
15. Inhaled Heparin: Therapeutic Efficacy and Recent Formulations.
Yildiz-Pekoz A; Ozsoy Y
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):143-156. PubMed ID: 28418758
[TBL] [Abstract][Full Text] [Related]
16. Inhaled Medicines: Past, Present, and Future.
Anderson S; Atkins P; Bäckman P; Cipolla D; Clark A; Daviskas E; Disse B; Entcheva-Dimitrov P; Fuller R; Gonda I; Lundbäck H; Olsson B; Weers J
Pharmacol Rev; 2022 Jan; 74(1):48-118. PubMed ID: 34987088
[TBL] [Abstract][Full Text] [Related]
17. Toxicological perspectives of inhaled therapeutics and nanoparticles.
Hayes AJ; Bakand S
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):933-47. PubMed ID: 24810077
[TBL] [Abstract][Full Text] [Related]
18. Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.
Xu Y; Thakur A; Zhang Y; Foged C
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33525500
[TBL] [Abstract][Full Text] [Related]
19. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
20. Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery.
Carneiro S; Müller JT; Merkel OM
Handb Exp Pharmacol; 2024; 284():313-328. PubMed ID: 38177399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
